NasdaqGS:ADPT
NasdaqGS:ADPTLife Sciences

How Genentech’s Collaboration Exit Has Changed the Investment Story at Adaptive Biotechnologies (ADPT)

On August 13, 2025, Genentech announced the termination of its Strategic Collaboration and License Agreement with Adaptive Biotechnologies, originally established to develop oncology cell therapy products, with an effective end date of February 9, 2026. This action releases Adaptive Biotechnologies from its exclusivity obligations in oncology cell therapies and is expected to result in the recognition of US$33.7 million in non-cash revenue in the second half of 2025. We'll explore how the...